Sign In
Buy SNY
$41.60
-0.180 (-0.431%)
At Close: Jun 23, 2026
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
12:26pm, Tuesday, 23'rd Jun 2026
Sanofi wins EU nod for Cenrifki in secondary progressive multiple sclerosis without relapses, while Wayrilz gets Japan nod for immune thrombocytopenia.
Sanofi Multiple Sclerosis Drug Gets EU Approval
01:37am, Tuesday, 23'rd Jun 2026
The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.
Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
01:15am, Tuesday, 23'rd Jun 2026
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopen
Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?
10:36am, Monday, 22'nd Jun 2026
SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
02:00am, Monday, 22'nd Jun 2026
Sanofi a ppoints Paulo Fontoura as Global Head of R&D Paris , June 22 , 2026. Sanofi today announced the appointment of Paulo F o ntoura , MD, PhD, FAAN, as Executi v e Vice
Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
06:31am, Friday, 19'th Jun 2026
Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated non-i
Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First
04:49pm, Monday, 15'th Jun 2026
Sanofi remains a compelling investment opportunity, driven by a robust pipeline and strong fundamentals. Sarclisa sales in Q1 of 2026 grew by 30.1% to $193.21 million; expansion with on-body injector
Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
01:15pm, Monday, 15'th Jun 2026
SNY wins FDA approval to expand Tzield's use in children with newly diagnosed stage 3 T1D, opening treatment to a broader patient group.
Sanofi: Information concerning the total number of voting rights and shares – May 2026
12:05pm, Monday, 15'th Jun 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
05:19pm, Friday, 12'th Jun 2026
The U.S. Food and Drug Administration approved Sanofi's injection to slow the loss of the body's own insulin production in children aged 8 to 17 years recently diagnos
New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
10:15am, Wednesday, 10'th Jun 2026
Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results
10:07am, Wednesday, 10'th Jun 2026
SNY halts its phase III MOBILIZE study after an interim review finds riliprubart unlikely to deliver sufficient efficacy in refractory CIDP patients.
Sanofi ends Phase 3 riliprubart trial after weak interim results
02:38am, Wednesday, 10'th Jun 2026
Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide
Sanofi to Stop Late-Stage Study of Immune-Disorder Drug
02:28am, Wednesday, 10'th Jun 2026
The termination is an early setback to new chief executive Belen Garijo, who took the helm last month.
